<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368887">
  <stage>Registered</stage>
  <submitdate>6/07/2015</submitdate>
  <approvaldate>17/07/2015</approvaldate>
  <actrnumber>ACTRN12615000741583</actrnumber>
  <trial_identification>
    <studytitle>Tart cherry concentrate in gout: a dose ranging study</studytitle>
    <scientifictitle>Determining the effects of tart cherry concentrate on gout flares and serum urate in patients with gout </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gout</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will receive  tart cherry concentrate as liquid at one of the following doses for 28 days: 1/2tbsp twice daily, 1 tbsp twice daily, 1.5tbsp twice daily or 2 tbsp twice daily all added in 250mls water and drunk. 
Adherence will be measured by self-report, empty bottle return and measurement of anthocyanins in plasma and urine</interventions>
    <comparator>2 drops of tart cherry concentrate as a liquid in 250mls water drunk twice daily</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The optimal dose of tart cherry concentrate to reduce serum urate</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patient adherence with tart cherry concentrate as assessed by self-report, empty bottle return and plasma and urine anthocyanin concentrations</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of tart cherry concentrate on gout flares as assessed by self-report flare diary.</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Gout as defined by American Rheumatism Association Criteria
2. Serum urate &gt;0.36mmol/l
3. Willing and able to provide informed consent
4. Willing and able to adhere to the study protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Type 1 diabetes
2. Creatinine clearance &lt;50mls/min
3. Diuretic use
4. allergic to cherries or cherry concentrate
5. Other serious medical conditions that preclude involvement </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2016</anticipatedstartdate>
    <actualstartdate>29/02/2016</actualstartdate>
    <anticipatedenddate>18/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <currentsamplesize>41</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>26/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>P.O.Box 4345
Christchurch 8014</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>P.O. Box 5541 Wellesley Street
Auckland 1411</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Gout is the most common form of arthritis in men &gt;40 years of age. The primary biochemical abnormality is elevated serum urate (hyperuricaemia). Hyperuricaemia (serum urate &gt;0.42mmol/L) results from either over production or under excretion of urate. When supersaturation levels are reached, uric acid crystals form and deposit in joints and periarticular tissues, where they cause damage through local mechanical pressure and acute/chronic inflammation. Over time, repeated attacks of gout lead to cartilage damage, bone erosion and permanent disability. The aim of gout management is to reduce serum urate levels to &lt;0.36mmol/L. If serum urate concentrations are consistently maintained at or below this level gouty attacks subside and tophi reduce in size and number . Nutritional supplementation with tart cherry concentrate has been suggested based on previous small studies that revealed a reduction in gout flares in patients consuming large amounts of cherries or tart cherry concentrate. These data are limited to observational studies and the only clinical trials are in small numbers of patients. Thus there is a need for prospective clinical trials of the effects of tart cherry concentrate in patients with gout. The aim of this study is to determine the most effective dose of tart cherry concentrate for use in a large clinical trial.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern B Health and Disability Ethics Committee of New Zealand</ethicname>
      <ethicaddress>C/- MEDSAFE, Level 6, Deloitte House
10 Brandon Street
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>15/09/2015</ethicapprovaldate>
      <hrec>15/NTB/133</hrec>
      <ethicsubmitdate>20/07/2015</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O. Box 4345
Christchurch 8014</address>
      <phone>+64 - 3-364- 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O. Box 4345
Christchurch 8014</address>
      <phone>+64 -3- 364- 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O. Box 4345
Christchurch 8014</address>
      <phone>+64 -3- 364- 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>Department of Medicine
University of Otago, Christchurch
P.O. Box 4345
Christchurch 8014</address>
      <phone>+64 - 3-364- 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>